Press Releases October 2, 2026 08:31 AM

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

20/20 BioLabs to Present at Maxim Growth Summit 2026, Engaging Institutional Investors

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
AIDX

20/20 BioLabs announced that its CEO and CFO will participate in the Maxim Growth Summit 2026 in New York, holding one-on-one meetings with institutional investors. The company specializes in AI-powered blood tests for early detection of cancers and chronic diseases and offers its OneTest product lines. The events aim to increase investor engagement and visibility ahead of potential growth milestones.

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
AIDX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • 20/20 BioLabs is participating in a high-profile investor summit, highlighting efforts to increase institutional investor engagement.
  • The company offers innovative AI-based blood tests for early cancer and disease detection, including multi-cancer and longevity testing.
  • Their tests use convenient, needle-free upper-arm collection devices, run in a CAP-accredited, CLIA-certified lab, supporting credibility and reliability.

Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York

GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Summit 2026, being held October 13 and 14, 2026 at the Hard Rock Hotel New York. The Summit’s healthcare program takes place Wednesday, October 14.

Mr. Cohen and Mr. Bergman will hold one-on-one meetings with institutional investors at the Summit and in additional meetings scheduled in New York that week.

Maxim Growth Summit 2026
Dates: October 13 and 14, 2026; healthcare program Wednesday, October 14
Location: Hard Rock Hotel New York, 159 West 48th Street, New York, NY 10036
Format: One-on-one investor meetings
Attendees: President and Chief Executive Officer Jonathan Cohen; Chief Financial Officer Alan Bergman
Conference Website: Click here

To schedule a one-on-one meeting with management at the Maxim Growth Summit or in New York that week, please contact your Maxim Group representative, email [email protected], or call Chris Tyson at (949) 491-8235.

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.

For more information visit https://2020biolabs.com.

Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]


Risks

  • Market adoption risk for new AI-powered diagnostic tests, potentially impacting revenue growth in healthcare diagnostics.
  • Regulatory risk surrounding laboratory testing and diagnostics compliance, which could affect product availability or market expansion.
  • Competitive risks from other companies developing similar or more advanced early detection diagnostic tests, impacting 20/20 BioLabs' market share.

More from Press Releases

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 Oct 2, 2026 Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group Oct 2, 2026 Hall Chadwick Acquisition Corp. and REEcycle Holdings, Inc. Announce Filing of Registration Statement on Form S-4 and Release Updated Investor Presentation Oct 2, 2026 Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting Oct 2, 2026 ATA Creativity Global Announces Receipt of a Bid Deficiency Notice from Nasdaq Oct 2, 2026